Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 242 of the 242 references it cites were found in a registry or an index; 29 of the 265 sources its claims cite were checked for support.

Vascular smooth muscle cells in atherosclerosis

Abstract

Vascular smooth muscle cells (VSMCs) are a major cell type present at all stages of an atherosclerotic plaque. According to the 'response to injury' and 'vulnerable plaque' hypotheses, contractile VSMCs recruited from the media undergo phenotypic conversion to proliferative synthetic cells that generate extracellular matrix to form the fibrous cap and hence stabilize plaques. However, lineage-tracing studies have highlighted flaws in the interpretation of former studies, revealing that these studies had underestimated both the content and functions of VSMCs in plaques and have thus challenged our view on the role of VSMCs in atherosclerosis. VSMCs are more plastic than previously recognized and can adopt alternative phenotypes, including phenotypes resembling foam cells, macrophages, mesenchymal stem cells and osteochondrogenic cells, which could contribute both positively and negatively to disease progression. In this Review, we present the evidence for VSMC plasticity and summarize the roles of VSMCs and VSMC-derived cells in atherosclerotic plaque development and progression. Correct attribution and spatiotemporal resolution of clinically beneficial and detrimental processes will underpin the success of any therapeutic intervention aimed at VSMCs and their derivatives.

Overview

CoChat Summary

TL;DR

This review argues that vascular smooth muscle cells (VSMCs) are a major source of plaque cells and extracellular matrix throughout atherosclerosis, with greater plasticity and clonality than previously recognized. Lineage-tracing studies show VSMC-derived cells adopt macrophage-like, foam cell, mesenchymal stem cell-like, and osteochondrogenic phenotypes, contributing both to plaque stability and instability.

Key findings

  • In murine atherosclerosis, VSMCs generate 30–70% of all plaque cells; in mice they contribute 30–70% of macrophage marker-positive cells, while in humans around 30–40% of CD68-positive cells and 50% of foam cells are VSMC-derived.
  • Plaque VSMC-derived cells arise by clonal expansion of relatively few medial VSMCs; most medial cells do not contribute to mouse plaque formation, and VSMC migration independent of proliferation is limited. Early cap VSMCs are highly proliferative and express αSMA, SMMHC, and PDGFRβ.
  • VSMCs adopt multiple phenotypes: fibrous cap ECM-producing cells, macrophage-like/foam cells, Sca1+ mesenchymal stem cell-like cells, and Runx2/Cbfa1+ osteochondrogenic/chondrocyte-like cells. VSMC-specific KLF4 deletion reduces switching to macrophage marker-positive cells and increases fibrous cap thickness and αSMA-positive cell content.
  • Human plaque VSMC telomeres are markedly shortened; one study reported more than 50% of all plaque cells to be senescent, with senescent cells appearing within 9 days of fat feeding, and genetic or pharmacological elimination of p16-positive cells reduced plaque formation and progression. Thin-cap fibroatheromas are defined by a fibrous cap of less than 65 µm; plaque rupture accounts for around 60–70% of thrombosis cases, erosion for most of the remainder, and calcified nodules for typically around 5%.

Methods

  • Narrative review; no primary data, sample, or statistical analysis are reported.
  • Synthesizes evidence from murine genetic lineage-tracing/fate-mapping studies, human autopsy and plaque histology, in vitro VSMC culture, and genetic association/functional genomics studies.
  • Main analysis is qualitative synthesis, with tables and boxes summarizing lineage tracing, embryonic origins, molecular mechanisms, and cell death.

Limitations

  • The paper states that extrapolating from mice to humans is difficult: diffuse intimal thickenings are absent in most animal models, fibroatheromas rarely rupture in mice, and an IL-1β-neutralizing antibody was deleterious to the fibrous cap in mice but beneficial in the human CANTOS trial.
  • Proving effects of senescent VSMCs is hampered by technical difficulties in mice: telomeres are approximately 10 times longer than in humans, in vitro SASP studies are problematic, and p16/SAβG detection is difficult, especially because macrophages in plaques express these markers.
  • The text also notes lacking definitive human evidence for anatomical segmentation of VSMC populations and for VSMCs as the source of fibrous cap ECM; as a review, conclusions await human single-cell/omics confirmation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41569-019-0227-9

Cites

242 of 242 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 10 Not valid · 107 Not checked · 57 Own results and interpretations

80 more claims · 6 with their cited sources checked

Create a free account to see all 188 claims and to verify the 236 references still open.

See all claims — free account
  • It may state two separate claims as one. 82
  • Probably not a substantial claim. 27
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 242 references

Cited by

See all 1,099

Metadata

Authors
Basatemur, G. L., Jørgensen, H. F., Clarke, M. C. H., Bennett, M. R., & Mallat, Z.
Affiliations
  • University of Cambridge (GB)
  • Inserm (FR)
Corresponding author
Mallat, Ziad
Venue
Nature Reviews Cardiology
Published
2019-06-26
Volume
16
Issue
12
Pages
727-744
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W2955108563
Cited by
1,099
References
242
Citations by year
2026: 118 · 2025: 193 · 2024: 175 · 2023: 140 · 2022: 201 · 2021: 158 · 2020: 100 · 2019: 12
FWCI
10.09
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
British Heart Foundation (PG/13/25/30014, PG/16/11/32021, PG/19/6/34153, FS/13/3/30038, PG/12/86/29930, PG/16/63/32307, FS/18/19/33371, RG/13/14/30314, FS/13/29/30024, FS/15/38/31516, FS/09/005/26845, FS/18/56/34177A, PG/17/9/32834, RG/16/8/32388, PG/11/112/29272)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
vascular smooth muscle cells, atherosclerosis, response-to-injury hypothesis, extracellular matrix, lineage tracing, clonal expansion, foam cells, macrophage-like cells, mesenchymal stem cells, osteochondrogenic differentiation
MeSH terms
Cell Plasticity, Animals, Extracellular Matrix, Humans, Phenotype, Cellular Senescence, Disease Progression, Myocytes, Smooth Muscle, Cell Proliferation, Atherosclerosis, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular smooth muscle cells in atherosclerosis. https://app.cochat.ai/papers/10.1038/s41569-019-0227-9
The paper
Basatemur, G. L., Jørgensen, H. F., Clarke, M. C. H., Bennett, M. R., & Mallat, Z. (2019). Vascular smooth muscle cells in atherosclerosis. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-019-0227-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.